Gross Profit Margin (Quarterly) Chart

Historical Gross Profit Margin (Quarterly) Data

View and export this data back to 2001. Start Trial.
Date Value
June 30, 2026 12.91%
March 31, 2026 11.02%
December 31, 2025 7.83%
September 30, 2025 4.61%
June 30, 2025 11.64%
March 31, 2025 10.00%
December 31, 2024 10.87%
September 30, 2024 6.81%
June 30, 2024 14.22%
March 31, 2024 10.99%
December 31, 2023 12.65%
September 30, 2023 8.60%
June 30, 2023 14.91%
March 31, 2023 10.76%
December 31, 2022 15.39%
September 30, 2022 9.51%
June 30, 2022 15.68%
March 31, 2022 10.83%
December 31, 2021 16.68%
September 30, 2021 9.06%
June 30, 2021 16.13%
March 31, 2021 9.64%
December 31, 2020 17.76%
September 30, 2020 10.82%
June 30, 2020 2.88%
Date Value
March 31, 2020 3.74%
December 31, 2019 15.10%
September 30, 2019 7.42%
June 30, 2019 13.87%
March 31, 2019 8.70%
December 31, 2018 15.87%
September 30, 2018 7.06%
June 30, 2018 14.06%
March 31, 2018 8.26%
December 31, 2017 16.17%
September 30, 2017 7.27%
June 30, 2017 13.88%
March 31, 2017 8.96%
December 31, 2016 16.33%
September 30, 2016 8.33%
June 30, 2016 14.05%
March 31, 2016 8.76%
December 31, 2015 14.97%
September 30, 2015 10.14%
June 30, 2015 13.33%
March 31, 2015 7.12%
December 31, 2014 15.95%
September 30, 2014 6.69%
June 30, 2014 12.32%
March 31, 2014 4.12%

Gross Profit Margin Definition

Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.

Read full definition.

Gross Profit Margin (Quarterly) Range, Past 5 Years

View Gross Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Gross Profit Margin (Quarterly) Benchmarks

View Gross Profit Margin (Quarterly) Benchmarks
Start Trial
Interpace Biosciences, Inc. 61.91%
PD-Rx Pharmaceuticals, Inc. --
Medical Marijuana, Inc. 83.04%
DiaSorin SpA --
Akso Health Group --